Department of Environmental and Occupational Health, School of Public Health, Université de Montréal, Montreal, Quebec, Canada; Centre de recherche en santé publique (CReSP), Montreal, Quebec, Canada.
Department of Environmental and Occupational Health, School of Public Health, Université de Montréal, Montreal, Quebec, Canada; Consultant Patrick Poulin Inc., Quebec City, Quebec, Canada.
J Pharm Sci. 2020 Oct;109(10):3190-3205. doi: 10.1016/j.xphs.2020.07.003. Epub 2020 Jul 8.
The main objective was to investigate the effect of albumin (ALB) and/or alpha-1-acid glycoprotein (AGP) on the hepatic clearance (CLh) of the drugs that bind, extensively, to both proteins. Isolated perfused livers from male Sprague Dawley rats (IPRL) were performed for perampanel (PER) and fluoxetine (FLU), using physiological solutions in four scenarios (n = 3 rats/scenario/drug): 1) without plasma proteins (WO), 2) with bovine ALB (40 g/L), 3) with bovine AGP (1 g/L), and 4) with mixture of both proteins (MIX). PER is poorly to moderately metabolized (hepatic extraction = 0.2-0.7), while FLU is highly metabolized (hepatic extraction = 0.8-0.99). The metabolic kinetics were fitted to the Michaelis-Menten model. For the PER, the parameters were V = 90, 16.4, 86.1 and 16.9 (nmol/min/g liver) and unbound K = 17, 1.7, 38.3 and 1.4 (μM) for the scenarios WO, with ALB, with AGP and with MIX, respectively. As for FLU, the parameters were V = 65.5, 18.5, 33.8 and 12.2 (nmol/min/g liver) and unbound K = 1.5, 0.03, 0.14 and 0.0466.31 (μM) in all four scenarios, respectively. In conclusion, a protein-mediated hepatic uptake likely occurred only at low concentrations for both drugs (i.e., therapeutic concentrations) in the presence of plasma proteins (except for the scenario of PER with AGP).
目的在于研究白蛋白(ALB)和/或α-1酸性糖蛋白(AGP)对与这两种蛋白广泛结合的药物在肝脏中的清除率(CLh)的影响。采用雄性 Sprague Dawley 大鼠(SD)离体灌流肝脏(IPRL),使用生理溶液在四种方案(n=3 只大鼠/方案/药物)中对依帕司他(PER)和氟西汀(FLU)进行实验:1)无血浆蛋白(WO),2)含有牛白蛋白(40g/L),3)含有牛 AGP(1g/L),4)混合两种蛋白(MIX)。PER 代谢程度差到中等(肝提取率=0.2-0.7),而 FLU 高度代谢(肝提取率=0.8-0.99)。代谢动力学符合米氏动力学模型。对于 PER,参数 V=90、16.4、86.1 和 16.9(nmol/min/g 肝脏),无结合态 K=17、1.7、38.3 和 1.4(μM),分别对应 WO、含 ALB、含 AGP 和含 MIX 这四种方案。对于 FLU,参数 V=65.5、18.5、33.8 和 12.2(nmol/min/g 肝脏),无结合态 K=1.5、0.03、0.14 和 0.0466.31(μM),分别对应所有四种方案。总之,在存在血浆蛋白的情况下(PER 与 AGP 方案除外),两种药物的肝摄取可能仅在低浓度时存在蛋白介导(即治疗浓度)。